Shots:

• The companies collaborated to evaluate Treos’ PolyPEPI1018 (Polypeptide cancer immunotherapy) + Roche’s atezolizumab (PD-L1-inhibitor) in P-I/II trial in patients with late-stage MSS mCRC which is expected to initiate in Q4’21
• Treos has completed a P- I/II OBERTO 101 study for PolyPEPI1018 as 1L maintenance setting in patients with MSS mCRC that demonstrates the therapy was safe & well-tolerated and induced T cell responses against multiple tumor targets
• Following the non-exclusive collaboration- Treos will conduct the study & maintains full ownership of PolyPEPI1018 whereas Roche to provide all required doses of atezolizumab

  Ref: Globe Newswire | Image: Roche